Branislav Kováčech

Author

Branislav Kováčech

Institute of Neuroimmunology of the Slovak Academy of Sciences ORCID

Also Known As

B Kovacech, B. KOVACECH, B. Kovacech, Branislav Kovacech, Branislav Kovačech, Branislav Kováčech

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Institute of Neuroimmunology of the Slovak Academy of Sciences Slovak Academy of Sciences AXON Neuroscience (Slovakia)AXON Neuroscience (Cyprus)Karolinska University Hospital

About

Branislav Kováčech is an author at Institute of Neuroimmunology of the Slovak Academy of Sciences specializing in medicine, neurodegenerative diseases, and alzheimer's disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	12	788
2	Natural Sciences	4	4	160
3	Social Sciences	3	3	105
4	Engineering	1	1	17
5	Health Sciences	1	1	298

Branislav Kováčech

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial Petr Novák, Reinhold Schmidt, Eva Kontseková, The Lancet Neurology VaccinationAlzheimer's DiseaseVaccine DevelopmentDementiaImmunology	2016	298
First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model Eva Kontseková, Norbert Žilka, Branislav Kováčech, Alzheimer s Research & Therapy	2014	243
ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease Petr Novák, Branislav Kováčech, Stanislav Katina, Nature Aging Neurodegenerative DiseasesAlzheimer's DiseaseActive ImmunotherapyMedicinePathological Tau	2021	168
FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease Petr Novák, Reinhold Schmidt, Eva Kontseková, Alzheimer s Research & Therapy	2018	140
Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer’s disease Eva Kontseková, Norbert Žilka, Branislav Kováčech, Alzheimer s Research & Therapy	2014	108
Microglia display modest phagocytic capacity for extracellular tau oligomers Petra Majerová, Monika Žilková, Zuzana Kazmerova, Journal of Neuroinflammation	2014	87
<i>EGT2</i> Gene Transcription Is Induced Predominantly by Swi5 in Early G<sub>1</sub> Branislav Kováčech, Kim Nasmyth, Tillman Schuster Molecular and Cellular Biology Ho GeneGeneticsGenomic MechanismMolecular GeneticsCell Cycle	1996	79
Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load Peter Koson, Norbert Žilka, Andrej Kováč, European Journal of Neuroscience	2008	74
Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias Jozef Hanes, Andrej Kováč, Hlin Kvartsberg, Neurology	2020	55
Therapeutic antibody targeting microtubule-binding domain prevents neuronal internalization of extracellular tau via masking neuron surface proteoglycans Petronela Weisová, Ondrej Cehlár, Rostislav Škrabana, Acta Neuropathologica Communications	2019	53

Page 1